Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy

Critical Reviews in Clinical Laboratory Sciences

Volumn 47, Issue 3, 2010, Pages 125-138

  Fredolini, Claudia ^a,b,c   Liotta, Lance A ^c   Petricoin, Emanuel F ^c  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

Individualized medicine; mass spectral imaging; mass spectrometry; nanotechnology; prostate cancer; prostate specific antigen; proteomics; reverse phase protein array

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN B; CALRETICULIN; ELONGATION FACTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FILAMIN A; GLUTATHIONE TRANSFERASE P1; HAPTOGLOBIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 90; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEOME; SQUAMOUS CELL CARCINOMA ANTIGEN; STAT PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE;

BODY FLUID; CANCER PATIENT; CARCINOGENESIS; EARLY DIAGNOSIS; HUMAN; MASS SPECTROMETRY; NANOTECHNOLOGY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; TECHNOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NANOTECHNOLOGY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 78650334799     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2010.503558     Document Type: Review

References (103)

1. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. Te International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680-688.
2. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906-913.
3. Ma RW, Chapman KJ. A systematic review of the efect of diet in prostate cancer prevention and treatment. Hum Nutr Diet 2009; 22: 187-199.
4. Drasch G, Schöpfer J, Schrauzer GN. Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective efects of selenium. Biol Trace Elem Res 2005; 103: 103-107.
5. Coussens LM, Wer Z. Infammation and cancer. Nature 2002;420:860-867.
6. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. Te infuence of chronic infammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176: 1012-1016.
7. Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu Rev Pathol 2006;1:243-271.
8. Zenzmaier C, Untergasser G, Berger P. Aging of the prostate epithelial stem/progenitor cell. Exp Gerontol 2008; 43: 981-985.
9. Barry MJ. Prostate-specifc-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344: 1373-1377.
10. Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res 2007; 175: 65-81.
11. Wilson SS, Crawford ED. Screening for prostate cancer: current recommendations. Urol Clin North Am 2004; 31: 219-26.
12. Tompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. J Urol 2009; 182: 499-507.
13. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
14. Roehrborn CG. Te utility of serum prostatic-specifc antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20Suppl 3: S19-S26.
15. Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia Arch Ital Urol Androl 2009; 81: 1-8.
16. Tompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl. Cancer Inst 2006; 98: 529-534. (Pubitemid 43898816)
17. Tompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specifc antigen level of ≤ 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
18. Te Early Detection Research Network: Investing in Translational Research on Biomarkers of Early Cancer and Cancer Risk, Fourth Report; NIH Publication No. 07-6135, January 2008. http://edrn.nci.nih.gov/docs.
19. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
20. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Diferential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007; 7: 3.
21. Lloyd MD, Darley DJ, Wierzbicki AS, Treadgill MD. Alpha-methylacyl-CoA racemase-an 'obscure' metabolic enzyme takes centre stage. FEBS J 2008; 275: 1089-1102.
22. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. Early identifcation of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419-1423.
23. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008;14:7790-7797.
24. Huggins C, Stevens Jr RE, Hodges C V. Studies on prostate cancer. II. Te efect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223.
25. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE Androgen deprivation therapy for the treatment of prostate cancer: consider both benefts and risks. Eur Urol 2009; 55: 62-75.
26. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000; 6: 220-233.
27. Hernandex J, Tompson IM. Diagnosis and treatment of prostate cancer. Med Clin North Am 2004; 88: 267-279.
28. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
29. Barry, M.J Screening for Prostate Cancer among Men 75 Years of Age or Older. N Engl J Med 2008; 359: 2515-2516.
30. Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T. Te potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol 2009;4: 235-252.
31. Lee J, Soper SA, Murray KK. Microfuidic chips for mass spectrometry-based proteomics. J Mass Spectrom 2009;44:579-593.
32. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, Chan AS, Chan AT. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009;6:123-134.
33. Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 2008;3:1796-1808.
34. Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3d, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol 2007;383:321-336.
35. Machida K, Tompson CM, Dierck K, Jablonowski K, Kärkkäinen S, Liu B, Zhang H, Nash PD, Newman DK, Nollau P, Pawson T, Renkema GH, Saksela K, Schiller MR, Shin DG., Mayer BJ. High-throughput phosphotyrosine pro-fling using SH2 domains. Mol Cell 2007;26:899-915.
36. Kim YJ, Feild B, Fitzhugh W, Heidbrink JL, Duf JW, Heil J, Ruben SM, He T. Reference map for liquid chromatography-mass spectrometry-based quantitative proteomics. Anal Biochem 2009;393:155-162.
37. Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics 2009;72:740-749.
38. Simpson KL, Whetton AD, Dive C. Quantitative mass spec-trometry-based techniques for clinical use: biomarker iden-tifcation and quantifcation. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1240-1249.
39. O'Farrell PH. High resolution two-dimensional electrophore-sis of proteins. J Biol Chem 1975; 250: 4007-4021
40. Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, and Maeda T. Proteome analysis of prostate cancer. Prostate Cancer and Prostatic Dis 2005; 8: 14-21.
41. Van den Bemd GJ, Krijgsveld J, Luider TM, van Rijswijk AL, Demmers JA, Jenster G. Mass spectrometric identif-cation of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 2006;5:1830-1839.
42. Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Toflon PJ, Camphausen K. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009;15:4292-4298.
43. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010;13:12-9.
44. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009;72:907-917.
45. Fung KY, Glode LM, Green S, Duncan MW. A comprehensive characterization of the peptide and protein constituents of human seminal fuid. Prostate 2004; 61: 171-181.
46. Petricoin EF, Belluco C, Araujo RP, Liotta LA. Te blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006; 6: 961-967.
47. ® surface enhanced laser desorption/ionization (SELDI) mass spec-trometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999; 2: 264-276.
48. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum pro-teomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-1578. (Pubitemid 35277282)
49. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fngerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614.
50. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Tompson IM, Tornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44-52.
51. McLerran D, Grizzle WE, Feng Z, Tompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Tornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60.
52. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Tompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profling by surface-enhanced laser desorption/ionization time-of-fight mass spec-trometry for the detection of prostate cancer. I: assessment of platform reproducibility. Clin Chem 2005; 51: 102-112.
53. Belluco C, Petricoin E, Peschle C, Liu C, Lowenthal M, Johann D, Lasebikan L, Ross-Rucker S, Lise M, Di Maggio C, Mammano E, Facchiano F, Nitti D, Garaci E, Mills G, Liotta L, Whiteley G. Serum proteomic mass spectrometry a highly sensitive and specifc discriminatory pattern for Stage I breast cancer. Ann Surg Oncol 2007; 14 2470-2476.
54. Liotta LA, Petricoin E F. Putting the "bio" back into biomark-ers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008; 54: 3-5.
55. Wright ME, Han DK, Aebersold R. Mass spectrometry-based expression profling of clinical prostate cancer. Mol Cell Proteomics 2005; 4: 545-554.
56. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW. 2DDIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009;8:942-957.
57. Vestergaard M, Tamiya E. A rapid sample pretreatment protocol: improved sensitivity in the detection of a low-abundant serum biomarker for prostate cancer. Anal Sci 2007;23:1443-1446.
58. Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Kunle Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics 2009;3:853-861.
59. Dekker LJ, Bosman J, Burgers PC, van Rijswijk A, Freije R, Luider T, Bischof RJ. Depletion of high-abundance proteins from serum by immunoafnity chromatography: a MALDI-FT-MS study. Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 65-69.
60. Geho DH, Luchini,A Garaci E, Belluco C, Petricoin EF, Liotta LA. Nanotechnology in clinical proteomics. Nanomedicine 2007; 2: 1-5.
61. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-Microglobulin is an androgen regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 2007; 13: 1979-1986.
62. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009; 72: 907-917.
63. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008; 7: 3329-3338.
64. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomark-ers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388-1394.
65. Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A. Humoral response profling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008; 7: 600-611.
66. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difer-ence gel electrophoresis for low abundance serum proteins. Proteomics 2005; 5: 3183-3192.
67. Quantitative assays for tryptic peptides belonging from 53 high and medium abundance serum proteins have been designed. Mol Cell Proteomics 2006; 5: 573-588.
68. Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, Choquet-Kastylevsky G. Lemoine. Clinical quan-titation of prostate-specifc antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chro-matography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. J Mol Cell Proteomics 2009; 8: 1006-1015.
69. Sparbier K, Wenzel T, Dihazi H, Blaschke S, Müller GA, Deelder A, Flad T, Kostrzewa M. Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrom-etry. Proteomics 2009; 9: 1442-1450.
70. Geho DH, Jones CD, Petricoin EF, Liotta LA. Nanoparticles potential biomarkers harvesters. Curr Opin Chem Biol 2006;10:56-61.
71. Hofman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;54:3-12.
72. Cavalieri F, Chiessi E, Villa R, Vigano L, Zafaroni N, Telling MF, Paradossi G. Novel PVA-based hydrogel micro-particles for doxorubicin delivery. Biomacromolecules 2008; 9: 1967-1973.
73. Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, Jones CD, Espina V, Patanarut A, Zhou W, Ross MM, Tessitore A, Petricoin EF 3d, Liotta LA. Smart hydrogel particles: biomarker harvesting: one-step afnity purifcation, size exclusion, and protection against degradation. Nano Lett 2008; 8: 350-361.
74. Longo C, Patanarut A, George T, Bishop B, Zhou W, Fredolini C, Ross MM, Espina V, Pellacani G, Petricoin EF 3d, Liotta LA, Luchini A. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 2009; 4: e4763.
75. Fredolini C, Meani F, Reeder KA, Rucker S, Patanarut A, Botterell PJ, Bishop B, Longo C, Espina V, Petricoin, EF III, Liotta LA, Luchini A. Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by cibacron blue F3G-A loaded hydrogel particles. Nano Research 2008; 1: 502-518.
76. Sutkeviciute I, Sereikaite J, Bumelis VA. Analysis of ciba-cron blue F3G-A interaction with therapeutic proteins by MALDI-TOF mass spectrometry. Biomed Chromatogr 2008; 22: 1001-1007.
77. Huggins C, Hodges C V. Studies on prostatic cancer. I. Te efect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
78. Niehans P: Prostata-Krebs wie Paraprostata-Hypertrophie sind Folgen hormonaler Störun-gen, die wir je früher je besser beeinfussen können. Verlag Hans Huber, Bern, 1940.
79. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991.
80. Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, Norstedt G, Bergman T, Pousette A. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate 2006; 66: 1235-1244.
81. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-7105.
82. Cappello F, Rappa F, David S, Anzalone R, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10, and MUC-2 presence and expression in prostate car-cinogenesis. Anticancer Res 2003; 3: 1325-1331.
83. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzén B, Volz D, Huwendiek S, Linder S, Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000; 21:1-9.
84. Rowland JG, Robson JL, Simon WJ, Leung HY, Slabas AR. Evaluation of an in vitro model of androgen ablation and identifcation of the androgen responsive proteome in LNCaP cells. Proteomics 2007; 7: 47-63.
85. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996; 274: 998-1001.
86. Paweletz CP, Liotta LA, Petricoin EF 3d. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 2001; 57: 160-163.
87. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989.
88. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin E F. Signal pathway pro-fling of prostate cancer using reverse phase protein arrays. Proteomics 2003;3 2142-2146.
89. Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle JD. Pathway biomarker profling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. Proteome Res 2009; 8: 3044-3054.
90. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3d, Liotta LA, Abati A. Te needle in the haystack: application of breast fne-needle aspirate samples to quantitative protein micro-array technology. Cancer 2007;111:173-184.
91. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, Brand RE, Haab BB. Multiplexed analysis of gly-can variation on native proteins captured by antibody micro-arrays. Nat Methods 2007;4:437-444.
92. Haab BB. Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics 2010;7:9-11.
93. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and protein susing MALDI-TOF MS. Anal Chem 1997;69:4751-4760.
94. Goodwin RJ, Pennington SR, Pitt AR. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics 2008;8:3785-3800.
95. Shimma S, Sugiura Y, Hayasaka T, Hoshikawa Y, Noda T, Setou M. MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. J Chromatogr B Analyt Technol Biomed Life Sci 2007;855:98-103.
96. Rauser S, Marquardt C, Balluf B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfer H, Walch A. Classifcation of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010;9: 1854-1863.
97. Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. Specifc MALDI imaging and profling for biomar-ker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 2007;6:4127-4134.
98. Chaurand P, Rahman MA, Hunt T, Mobley JA, Gu G, Latham JC, Caprioli RM, Kasper S. Monitoring mouse prostate development by profling and imaging mass spectrom-etry. Mol Cell Proteomics 2008;7:411-423.
99. Schwamborn K, Krieg RC, Reska M, Jakse G, Knuechel R, Wellmann A. Identifying prostate carcinoma by MALDI-imaging. Int J Mol Med 2007;20:155-159.
100. Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, Clements MA, Drake RR, Semmes OJ. Imaging mass spectrometry of a specifc fragment of mitogen-acti-vated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 2009;15:5541-551.
101. Tiery G, Shchepinov MS, Southern EM, Audebourg A, Audard V, Terris B, Gut IG. Multiplex target protein imaging in tissue sections by mass spectrometry-TAMSIM. Rapid Commun Mass Spectrom 2007;21:823-829.
102. Baker MJ, Brown MD, Gazi E, Clarke NW, Vickerman JC, Lockyer NP. Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. Analyst 2008;133:175-179.
103. Lechene C, Hillion F, McMahon G, Benson D, Kleinfeld AM, Kampf JP, Distel D, Luyten Y, Bonventre J, Hentschel D, Park KM, Ito S, Schwartz M, Benichou G, Slodzian G. High-resolution quantitative imaging of mammalian and bacterial cells using stable isotope mass spec-trometry. J Biol 2006; 5:20.